Prasco Laboratories, a US-based privately held healthcare company, announced on Friday that it has introduced the Authorised Generic of ZIOPTAN (tafluprost ophthalmic solution) 0.0015% in collaboration with US-based Thea Pharma, Inc., an independent pharmaceutical company.

The product is therapeutically equivalent to ZIOPTAN, marketed under the Prasco label, and will be widely offered in United States pharmacies. It is a prostaglandin analogue intended to decrease elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Prasco chief executive officer, Chris Arington, said, 'This partnership with Théa expands our ophthalmic portfolio, giving patients greater access and affordability to critical prescriptions they need.'